Skip to Content
Diagnosed with Prostate Cancer? Learn about your treatment options >>

Histrelin Pregnancy and Breastfeeding Warnings

Histrelin is also known as: Supprelin LA, Vantas

Medically reviewed on May 23, 2017

Histrelin Pregnancy Warnings

US: Contradicted in females who are or may become pregnant
UK: Not indicated for use in adult women.

US FDA pregnancy category: X

This drug can cause fetal harm when administered to a pregnant woman. Spontaneous abortions may occur. Major fetal abnormalities, increased fetal mortality, decreased fetal weights, and reduced fertility have been observed in animal studies. In nonclinical studies, histrelin was teratogenic and fetotoxic.

US FDA pregnancy category X: Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

See references

Histrelin Breastfeeding Warnings

Not indicated for use in adult women.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.
  2. "Product Information. Supprelin LA (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.

References for breastfeeding information

  1. "Product Information. Vantas (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.
  2. "Product Information. Supprelin LA (histrelin)." Endo Pharmaceuticals (formally Indevus Pharmaceuticals Inc), Lexington, MA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide